Table 5 Comparison of pCR and bpCR in different subgroups of this analysis to large meta-analysis databases
Subgroup | CTNeoBC (1) | This trial | Subgroup | EBCTCG (10) | This trial |
|---|---|---|---|---|---|
pCR | pCR | CCR | bpCR (yT0/Tis) | ||
cT1 | 18.3% (15.7–21.2%) | 100.0% | cT1 | 34.6% | 100.0% |
cT2 | 19.9% (19.0–20.9%) | 40.5% (31.4–49.7%) | cT2 | 29.7% | 47.7% (38.5–57.0%) |
cT3 | 13.0% (11.7–14.3%) | 26.2% (19.1–33.2%) | cT3-4 | 13.3% | 29.5–36.2% |
cT4 | 14.5–16.0% (12.1–19.6%) | 24.4% (14.8–33.9%) |  |  | (19.4–44.0%) |
cN0 | 18.8% (17.9–19.8%) | 32.2% (25.2–39.2%) | cN0 | 28.6% | 38.6% (31.3–45.9%) |
cN +  | 16.9% (15.9–17.9%) | 30.0% (23.1–36.9%) | cN +  | 27.2% | 39.4% (32.1–46.8%) |
Ductal | 15.5% (14.7–16.3%) | 33.3% (27.3–39.3%) |  |  |  |
Lobular | 7.8% (6.4–9-4%) | 25.8% (15.2–36.3%) |  |  |  |
Grade I | 7.8% (6.4–9-4%) | 16.7% (1.8–31.6%) | Grade I | 20.9% | 16.7% (1.8–31.6%) |
Grade II | 12.3% (11.3–13-3%) | 26.8% (19.4–34.2%) | Grade II | 36.0% | 31.9% (24.1–39.7%) |
Grade III | 25.8% (24.3–27.4%) | 36.3% (29.3–43.4%) | Grade III | 44.6% | 47.5% (40.2–54.8%) |
HR + /HER2-G1/2 | 7.5% (6.3–8.7%) | 15.4% (5.6–25.2%) | ER + G1-2 | 31.4% | 15.4% (5.6–25.2%) |
HR + /HER2-G3 | 16.2% (13.4–19-3%) | 25.3% (18.6–32.0%) | ER + G3 | 34.9% | 32.1% (24.9–39.3%) |
HR + /HER2 + (no H) | 18.3% (15.5–21.3%) | 28.0% (10.4–45.6%) | ER- G1-2 | 37.2% | NA |
HR-/HER2 + (no H) | 30.2% (26.0–34.5%) | 43.5% (23.2–63.7%) | ER- G3 | 52.9% | NA |
Triple negative | 33.6% (30.9–36.4%) | 45.5% (32.3–58.6%) |  |  |  |
|  |  |  | Age < 45 y | 29.8% | 54.5% (42.5–66.6%) |
|  |  |  | Age 45–55 y | 29.0% | 38.0% (29.6–46.4%) |
|  |  |  | Age > 55 y | 25.8% | 32.9% (25.3–40.5%) |
|  |  |  | No Anthracycline or Taxane | 18.5% | 45.0% (35.6–54.3%) |
|  |  |  | Anthracycline, no Taxane | 26.0% | 39.1% (32.4–45-8%) |
|  |  |  | Anthracycline and Taxane | 41.0% | 20.0% (− 0.2–40.2%) |